CTI BioPharma Corp. (CTIC) was a big mover last session, as the company saw its shares rise nearly 12% on the day. The upside came after the company released data from a Phase 3 registration-directed trial that examined pacritinib to treat myleofibrosis. The news led to far more shares changing hands than in a normal session, breaking the recent trend of the company as the stock is now trading above the volatile price range of $1.66 to $1.94 over the past one-month time frame.
The stock has witnessed four upward estimate revisions in the past 30 days. The Zacks Consensus Estimate has also moved up over the same time frame, suggesting that more solid trading could be ahead for CTI BioPharma. So make sure to keep an eye on this stock going forward to see if the latest jump can turn into more strength down the road.
CTI BioPharma carries a Zacks Rank #2 (Buy), while its Earnings ESP is positive.
Investors interested in the med-drugs industry may also consider Indivior PLC (INVVY), sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment